Dyne Therapeutics Inc (DYN NASDAQ) stock market data APIs
$11.9498
0.19(1.6%)
as of May 2, 2025
Dyne Therapeutics Inc Financial Data Overview
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Prev. Close
11.9498
Open
12.1362
High
12.5147
Low
11.7568
52 wk Range
6.36-47.45
Market Cap
1 348 M
Shares Outstanding
114 M
EPS
-0.88
Beta
1.209
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dyne Therapeutics Inc data using free add-ons & libraries
Get Dyne Therapeutics Inc Fundamental Data
Dyne Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -342 212 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-03
- EPS/Forecast: -0.912
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dyne Therapeutics Inc News
New
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned f...
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans. Continue Reading View Comments
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHA...
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
Dyne Therapeutics, Inc. Vikram Ranade, PhDVikram Ranade, PhD, Chief Business Officer (CBO) of Dyne Therapeutics Ranjan Batra, PhDRanjan Batra, PhD, Chief Scientific Officer (CSO), of Dyne Therapeuti...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
